The present invention relates to a novel antibody or an antigen binding fragment thereof that specifically binds to a human hepatocyte growth factor receptor (c-Met), and a composition for preventing or treating cancer, wherein the antibody shows an excellent cancer cell proliferation inhibitory activity and a remarkably excellent anticancer activity even by a little amount thereof, thus effectively preventing or treating cancer.

Antibodies and compositions against IGF-1R and uses thereof are provided herein.

Disclosed herein are compounds, combinations, and kits that can be used to more quickly remove radionuclides from a subject, preferably a human being. Said compounds, combinations and kits can also be used to increase the tumor-to-blood ratio, or to more rapidly and/or conveniently achieve such an increase, of a label in targeted imaging or targeted radiotherapy in a subject, preferably a human being.

The present invention provides a protein construct comprising: a) at least two monomers each of which comprises a C-type lectin domain of CD23, wherein each monomer can bind to IgE; and b) an entity which can bind to the neonatal Fc receptor (FcRn); wherein said protein construct comprises a linker, and wherein said linker is used to link said monomer comprising a C-type lectin domain of CD23 to said entity which can bind to FcRn. Therapeutic uses of the constructs, for example in anti-IgE therapy or for use in the treatment or prevention of an IgE related disease or condition are also provided.

Disclosed herein are anti-CTLA-4 antibodies possessing superior binding and biological activities relative to ipibmumab and tremelimumab, pharmaceutical compositions comprising such. Also provided herein are therapeutic and diagnostic applications of such anti-CTLA-4 antibodies.

Provided herein are agents, such as antibodies and chimeric antigen receptors, that target HSP70. Methods of treating cancer are provided, comprising administering to a patient in need thereof an effective amount of an HSP70-targeting agent. The HSP70-specific antibody may enhance uptake of HSP70 by antigen presenting cells.

Antibody-drug conjugates, compositions thereof, and methods use. The antibody-drug conjugates include a fusion protein comprising an antibody covalently linked to an ADP-ribosyl cyclase protein via a peptide linker moiety at one or more of a C-terminus or N-terminus of a heavy or light chain of the antibody, a NAD or NMN analogue, and a payload such that the NAD or NMN analogue is conjugated to both the payload and the ADP-ribosyl cyclase protein.

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Provided herein are novel polypeptides, methods for their production and uses thereof.

The present invention relates to antibodies which bind to TNFα and comprise a modified Fc region. The antibodies of the invention have improved resistance against proteolytic degradation and good effector functions and/or pharmacokinetic properties.